RENOVARO INC (RENB)
US29350E1047 - Common Stock
Taking everything into account, RENB scores 1 out of 10 in our fundamental rating. RENB was compared to 564 industry peers in the Biotechnology industry. RENB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RENB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year RENB has reported negative net income.
In the past year RENB has reported a negative cash flow from operations.
RENB had negative earnings in each of the past 5 years.
RENB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
RENB has a Return On Assets of -94.96%. This is in the lower half of the industry: RENB underperforms 74.51% of its industry peers.
With a Return On Equity value of -117.94%, RENB perfoms like the industry average, outperforming 41.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.96% | ||
| ROE | -117.94% | ||
| ROIC | N/A |
ROA(3y)-72.08%
ROA(5y)-46.53%
ROE(3y)-85.62%
ROE(5y)-54.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RENB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RENB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RENB has been increased compared to 5 years ago.
Compared to 1 year ago, RENB has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -2.01, we must say that RENB is in the distress zone and has some risk of bankruptcy.
RENB has a Altman-Z score of -2.01. This is comparable to the rest of the industry: RENB outperforms 52.42% of its industry peers.
There is no outstanding debt for RENB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.01 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
RENB has a Current Ratio of 0.08. This is a bad value and indicates that RENB is not financially healthy enough and could expect problems in meeting its short term obligations.
RENB has a Current ratio of 0.08. This is amonst the worse of the industry: RENB underperforms 98.74% of its industry peers.
RENB has a Quick Ratio of 0.08. This is a bad value and indicates that RENB is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.08, RENB is not doing good in the industry: 98.56% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.08 |
3. Growth
3.1 Past
RENB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.47%.
EPS 1Y (TTM)-33.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RENB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for RENB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RENOVARO INC
NASDAQ:RENB (1/3/2025, 8:00:01 PM)
After market: 0.98 +0.05 (+5.83%)0.926
+0.16 (+21.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners9.68%
Inst Owner ChangeN/A
Ins Owners12.12%
Ins Owner Change-20.2%
Market Cap146.97M
AnalystsN/A
Price TargetN/A
Short Float %5%
Short Ratio4.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.5 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.93
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS0.62
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -94.96% | ||
| ROE | -117.94% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-72.08%
ROA(5y)-46.53%
ROE(3y)-85.62%
ROE(5y)-54.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.08 | ||
| Quick Ratio | 0.08 | ||
| Altman-Z | -2.01 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.76%
Cap/Depr(5y)253.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-101.7%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.87%
OCF growth 3YN/A
OCF growth 5YN/A